Belviq Recall: Eisai Voluntarily Recalls Diet Drug and Weight Loss Medication Beliviq and Belviq XR (Lorcaserin) Over Possible Cancer Risk.
On February 13, 2020, the U.S. Food and Drug Administration (FDA) reportedly requested that the manufacturer of Belviq, Belviq XR (lorcaserin) voluntarily withdraw the weight-loss drug from the U.S. market since a safety clinical trial showed an increased occurrence of cancer. According to the FDA, Eisai Inc. requested to voluntarily withdraw or recall Belviq and Belviq XR.
The FDA reported that a range of cancer types, with several different types of cancers, occurred more frequently in the clinical trial of patients who took lorcaserin, including pancreatic cancer, colorectal cancer, and lung cancer.
In January 2020 the FDA earlier announced it was reviewing clinical trial data and alerted the public about a possible risk of cancer associated with lorcaserin based on preliminary analysis of the data.
If you took recalled Belviq or Belviq XR (lorcaserin) and were diagnosed with cancer, you may be able to seek compensation from a Belviq recall lawsuit.
If You Have Thoughts On The Belviq Recall, Share Your Comments Below.